Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Profound Medical PROF shares soared 9.5% in the last trading session to close at $8.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement ...

Profound Medical (Nasdaq: PROF) has received FDA 510(k) clearance for its second AI model aimed at treating prostate cancer. Profound Medical is a Toronto-based company, which specializes in ...

Investors might want to bet on Profound Medical (PROF), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- With reference to its press release dated June 30, 2017, Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) announced today that all closing ...

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...